Desipramine hydrochloride - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for desipramine hydrochloride and what is the scope of freedom to operate?

Desipramine hydrochloride is the generic ingredient in three branded drugs marketed by Sanofi Aventis Us, Actavis Totowa, Alembic, Amneal Pharms Co, Ani Pharms, Chartwell Rx, Heritage, Novast Labs, Usl Pharma, and Validus Pharms, and is included in eighteen NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for desipramine hydrochloride. Ten suppliers are listed for this compound.

Summary for desipramine hydrochloride

US Patents:	0
Tradenames:	3
Applicants:	10
NDAs:	18
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	89
Clinical Trials:	61
Patent Applications:	2,258
What excipients (inactive ingredients) are in desipramine hydrochloride?	desipramine hydrochloride excipients list
DailyMed Link:	desipramine hydrochloride at DailyMed

Recent Clinical Trials for desipramine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University College, London	Phase 3
London North West Healthcare NHS Trust	Phase 3
University Hospital Plymouth NHS Trust	Phase 3

See all desipramine hydrochloride clinical trials

Pharmacology for desipramine hydrochloride

Drug Class	Tricyclic Antidepressant

Medical Subject Heading (MeSH) Categories for desipramine hydrochloride

Adrenergic Uptake Inhibitors
Antidepressive Agents, Tricyclic
Enzyme Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for desipramine hydrochloride

N06AA	Non-selective monoamine reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for desipramine hydrochloride

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	DESIPRAMINE HYDROCHLORIDE	desipramine hydrochloride	TABLET;ORAL	209785-002	Jul 7, 2021	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Heritage	DESIPRAMINE HYDROCHLORIDE	desipramine hydrochloride	TABLET;ORAL	207433-006	May 5, 2016	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Heritage	DESIPRAMINE HYDROCHLORIDE	desipramine hydrochloride	TABLET;ORAL	207433-005	May 5, 2016	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-007	Feb 11, 1982	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Alembic	DESIPRAMINE HYDROCHLORIDE	desipramine hydrochloride	TABLET;ORAL	209785-001	Jul 7, 2021	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for desipramine hydrochloride

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-006	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-005	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Validus Pharms	NORPRAMIN	desipramine hydrochloride	TABLET;ORAL	014399-004	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Sanofi Aventis Us	PERTOFRANE	desipramine hydrochloride	CAPSULE;ORAL	013621-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Sanofi Aventis Us	PERTOFRANE	desipramine hydrochloride	CAPSULE;ORAL	013621-002	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.